





Newly Reported Substances: The following is a selection of substances reported to NFLIS-Drug for the first time between October 1, 2024, and December 31, 2024.




States from which each new substance was identified are noted in parentheses following the chemical name.


Desalkylquazepam (Ohio)




Ethylene Etonitazene (Ohio)



5-Methyl Etodesnitazine (Ohio)




BTMPS¹ (reported in all states except Iowa*, Minnesota*, Wyoming*)




¹ Bis(2,2,6,6-tetramethyl-4-piperidinyl) Sebacate

3-Methyl PCP (South Carolina)



Chloro-PiHP (Florida)






Snapshot of Drug Reports Received by NFLIS-Drug

These tables present the top drugs in each category that drug laboratories received, analyzed, and reported to NFLIS-Drug between October 1, 2024, and December 31, 2024. (Percentages are of all reports in the same period.)

Phenethylamines	12,948 (25.22%)	Fentanyl and Fentanyl-related Compounds	6,987 (13.61%)	Psychedelics	459 (0.89%)	Synthetic Cathinones	371 (0.72%)
Methamphetamine	12,707 (24.75%)	Fentanyl	5,834 (11.36%)	Psilocin	299 (0.58%)	N-isopropyl Butylone	178 (0.35%)
Amphetamine	219 (0.43%)	Fluorofentanyl ²	637 (1.24%)	Psilocin/Psilocybin	69 (0.13%)	Dipentylone	98 (0.19%)
Lisdexamfetamine	12 (0.02%)	4-ANPP	307 (0.60%)	Psilocybin	63 (0.12%)	alpha-PiHP	32 (0.06%)
		Acetyl fentanyl	74 (0.14%)	Lysergic acid diethylamide (LSD)	28 (0.05%)	Pentylone	19 (0.04%)
						N-Cyclohexylmethylone	12 (0.02%)
Cocaine	9,281 (18.08%)	Heroin	1,351 (2.63%)				

² Includes all positional and nonspecified isomers as reported by participating laboratories.

Notable Trends, by date Submitted to Laboratory



Full substance names are available on the NFLIS website. View a complete list of newly reported substances by clicking or scanning the QR code. Contact us at NFLIS@dea.gov.



DEA GUARDS METHOD

Click or scan the QR code to learn more about GUARDS.

Data Disclaimer: Substances identified by federal, state, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in January 2025. Data in the Newly Reported Substances and Snapshot of Drug Reports Received by NFLIS-Drug sections include only drugs reported to NFLIS-Drug between October 1, 2024, and December 31, 2024. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.deadiversion.usdoj.gov/nflisdata/docs/2k17NFLISQA.pdf>.

